ElexoPharm Receives € 2.1 Million EUROSTARS Grant

23-May-2012 - Germany

A EUROSTARS grant of €2.1 million has been awarded to a transnational consortium consisting of Khondrion BV ( Nijmegen), Radboud University Nijmegen Medical Centre (RUNMC, Nijmegen), Pharmacelsus GmbH (Saarbruecken) and ElexoPharm GmbH (Saarbruecken). This grant, which for the German partners comes from the German Federal Ministry of Education and Research (BMBF), will support an ambitious scientific collaboration to discover treatments for mitochondrial diseases with high unmet medical need (approximately 300,000 patients in industrialized countries).

During the three years’ grant period, each partner of this multidisciplinary European consortium will contribute its expertise to reach their shared goal. ElexoPharm is responsible for the design and synthesis of small pharmaceutical molecules with state of the art in silico modelling and medicinal chemistry technologies. Khondrion acts as the consortium leader and will carry out the in vitro evaluation of the new chemical entities, including screening in their cell-based mitochondrial disease models. Pharmacelsus is going to perform ADME, toxicity and PK studies in their GLP-certified facilities, and the RUNMC will evaluate the best compounds regarding in vivo efficacy in preclinical studies to achieve Proof of Principle.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances